Evidence map›Paper›PMID 42375169›Full record

ArticleOncology letters2026

Safe management of sequential chemotherapy in a hemodialysis patient with metastatic colorectal cancer: A case report.

Rika Sasaki, Nobuhito Hara, Yoshiki Kojitani, Yumi Yoshii, Masahide Ota, Shunsuke Okazaki, Masayuki Takeda

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncology letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Rika SasakiDepartment of Cancer Genomics and Medical Oncology, Nara Medical University, Kashihara, Nara 634-8521, Japan.
Nobuhito HaraDepartment of Cancer Genomics and Medical Oncology, Nara Medical University, Kashihara, Nara 634-8521, Japan.
Yoshiki KojitaniDepartment of Cancer Genomics and Medical Oncology, Nara Medical University, Kashihara, Nara 634-8521, Japan.
Yumi YoshiiDepartment of Cancer Genomics and Medical Oncology, Nara Medical University, Kashihara, Nara 634-8521, Japan.
Masahide OtaDepartment of Cancer Genomics and Medical Oncology, Nara Medical University, Kashihara, Nara 634-8521, Japan.
Shunsuke OkazakiDepartment of Cancer Genomics and Medical Oncology, Nara Medical University, Kashihara, Nara 634-8521, Japan.
Masayuki TakedaDepartment of Cancer Genomics and Medical Oncology, Nara Medical University, Kashihara, Nara 634-8521, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Managing chemotherapy in hemodialysis (HD) patients is clinically challenging due to altered pharmacokinetics and a higher risk of severe toxicity. Evidence on drug selection and dose titration in cancer patients undergoing HD is limited. The present study reported the case of a patient with metastatic colorectal cancer who safely received first-to third-line chemotherapy while on maintenance HD. Treatment was individualized based on drug characteristics and the dialysis schedule. Initial therapy consisted of reduced-dose capecitabine (1,000 mg/m

Indexed as

chemotherapydose adjustmenthemodialysismetastatic colorectal cancer

Identifiers

PMID42375169
PMCPMC13311902

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.